Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that the firms are investigating legal claims against the officers and Board of Directors of Edwards Lifesciences Corporation (“Edwards Lifesciences” or “Company”) (NYSE:EW) related to potential securities violations between April 25, 2012 and April 23, 2013 (the “Class Period”).
If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com , or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at firstname.lastname@example.org. There is no cost or fee to you.
In a recently filed federal class action complaint, Edwards Lifesciences and certain of its officers and directors were charged with violating certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges that defendants’ misrepresented, among other things, that (a) the adoption of SAPIEN was weaker than the Company proclaimed due to concerns among physicians over the risks and complexity of the procedure to implant the valve; (b) the Company’s outlook for sales and earnings per share was significantly weaker than the optimistic guidance Defendants offered to investors; and (c) as a result of the above, the positive statements released by Defendants regarding the Company’s operations, forecasts and outlook were unfounded. According to the complaint, when the truth came out, the share price of Edwards Lifesciences dropped dramatically.
“Recent revelations about alleged improper business practices and procedures regarding key aspects of Edwards Lifesciences’ business and other misleading financial statements have prompted the firms to investigate possible breaches of fiduciary duties and other violations of state law by Edwards Lifesciences’ officers and directors. Based on our investigation, we are prepared to pursue litigation to preserve the company and the value of Edwards Lifesciences stock for all shareholders,” said shareholder rights attorney Willie Briscoe.